Thyroid · 2014 · 51 citations · 17 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular DiagnosticsMolecular OncologyMutation AnalysisThyroid CancerThyroid CytologyThyroid Nodule EvaluationThyroid UltrasonographyThyroid UltrasoundBraf V600 MutationsBraf V600e MutationGermline Mutation TestingMutation TestingPoint MutationsThyroid Cancer PathologyThyroid Nodule CytologyThyroid Nodule Cytopathology
BACKGROUND: A molecular profile including BRAF and RAS mutations as well as RET/PTC rearrangement evaluation has been proposed to provide an accurate presurgical assessment of thyroid nodules and to reduce the number of unnecessary diagnostic surgeries, sparing patients' health and saving healthcare resources. However, the application of such molecular analyses may provide different results among different centers and populations in real-life settings. Our aims were to evaluate the diagnostic utility of assessing the presence of BRAF and RAS mutations and RET/PTC1 and RET/PTC3 rearrangements in all cytological categories in an Italian group of thyroid nodule patients assessed prospectively, and to understand whether and which mutation testing might be helpful in cytologically indeterminate nodules. METHODS: A total of 911 patients were submitted to ultrasound and fine-needle aspiration biopsy examination. Cytological evaluation was performed in parallel with molecular testing and compared to pathological results in 940 thyroid nodules, including 140 indeterminate lesions. RESULTS: BRAF mutation testing provided the best contribution to cancer diagnosis, allowing the disease to be detected at an early stage, and identifying indeterminate nodules in which diagnostic lobectomy could be spared. On the contrary, RAS and RET/PTC analysis did not further increase diagnostic sensitivity for thyroid cancer. In addition, we found RET/PTC rearrangements in benign lesions, indicating that this molecular marker might not be useful for the detection of thyroid cancer. CONCLUSION: BRAF(V600E) mutation analysis is superior to RAS point mutations and evaluation of RET/PTC rearrangements in the diagnosis of thyroid cancer, even in indeterminate lesions.
17
The Bethesda System for Reporting Thyroid Cytopathology
Edmund S. Cibas, Syed Z. Ali · Thyroid · 2009 · 1.3K citations
Medicine, Endocrinology, Pathology +17
Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
Mingzhao Xing, Ali S. Alzahrani, Kathryn A. Carson et al. · JAMA · 2013 · 926 citations
Yuri E. Nikiforov, N. Paul Ohori, Steven P. Hodak et al. · The Journal of Clinical Endocrinology & Metabolism · 2011 · 789 citations · Full text